Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

Y0001182

Captopril für die Systemeignung

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Captopril, N-[(S)-3-Mercapto-2-methylpropionyl]-L-prolin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C9H15NO3S
CAS-Nummer:
62571-86-2
Molekulargewicht:
217.29
Beilstein:
477887
MDL-Nummer:
MFCD00168073
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329831295
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

captopril

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

104-108 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChIKey

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Angaben zum Gen

human ... ACE(1636)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Captopril for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Angiotensin Converting Enzyme-Hemmer. Hemmt die Bildung von Angiotensin II, einem bioaktiven Peptid, das die Angionese stimuliert und die Mikrogefäßdichte erhöht.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1091200

Captopril, United States Pharmacopeia (USP) Reference Standard

1091221

Captoprildisulfid, United States Pharmacopeia (USP) Reference Standard

PHR1307

Captopril, Pharmaceutical Secondary Standard; Certified Reference Material

C0430000

Captopril, European Pharmacopoeia (EP) Reference Standard

Y0000435

Captopril Unreinheit E, European Pharmacopoeia (EP) Reference Standard

Y0001221

Captopril Unreinheit D, European Pharmacopoeia (EP) Reference Standard

Y0001219

Captopril Unreinheit B, European Pharmacopoeia (EP) Reference Standard

Y0001220

Captopril Unreinheit C, European Pharmacopoeia (EP) Reference Standard

Y0001450

Captopril Unreinheit J, European Pharmacopoeia (EP) Reference Standard

BP538

Captopril, British Pharmacopoeia (BP) Reference Standard

BP500

Captoprildisulfid, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H341,H360F

Gefahreneinstufungen

Muta. 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Johannes J Kovarik et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 30(1), 115-123 (2014-08-12)
Blockade of the renin-angiotensin system (RAS) exerts beneficial effects in patients with mild-to-moderate chronic kidney disease, yet evidence suggesting a similar benefit in haemodialysis (HD) patients is not available. Furthermore, knowledge of the effects of RAS blockade on systemic RAS
Samir Attoub et al.
Annals of the New York Academy of Sciences, 1138, 65-72 (2008-10-08)
Lung cancer is the most common form of cancer in the world, and 90% of patients die from their disease. The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease
A O Nur et al.
International journal of pharmaceutics, 194(2), 139-146 (2000-02-29)
The development of oral sustained or controlled release dosage form of captopril has been an interested topic of research for a long period of time. Difficulties encountered with such topic based on the fact that the drug is freely water
R I Ogilvie et al.
The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)
Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)
Antonio C M Camargo et al.
Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)
The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.